DK2566505T3 - Fremføring af kolesterylester til steroidogene væv - Google Patents

Fremføring af kolesterylester til steroidogene væv Download PDF

Info

Publication number
DK2566505T3
DK2566505T3 DK11720265.5T DK11720265T DK2566505T3 DK 2566505 T3 DK2566505 T3 DK 2566505T3 DK 11720265 T DK11720265 T DK 11720265T DK 2566505 T3 DK2566505 T3 DK 2566505T3
Authority
DK
Denmark
Prior art keywords
steroidogen
cholesterylestes
tissue
application
steroidogen tissue
Prior art date
Application number
DK11720265.5T
Other languages
English (en)
Inventor
Bruce J Auerbach
Reynold Homan
Brian KRAUSE
Original Assignee
Alphacore Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphacore Pharma Llc filed Critical Alphacore Pharma Llc
Application granted granted Critical
Publication of DK2566505T3 publication Critical patent/DK2566505T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK11720265.5T 2010-05-06 2011-05-06 Fremføring af kolesterylester til steroidogene væv DK2566505T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190910P 2010-05-06 2010-05-06
PCT/US2011/035500 WO2011140429A1 (en) 2010-05-06 2011-05-06 Delivery of cholesteryl ester to steroidogenic tissues

Publications (1)

Publication Number Publication Date
DK2566505T3 true DK2566505T3 (da) 2020-01-20

Family

ID=44121177

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11720265.5T DK2566505T3 (da) 2010-05-06 2011-05-06 Fremføring af kolesterylester til steroidogene væv

Country Status (23)

Country Link
US (2) US20130045194A1 (da)
EP (1) EP2566505B1 (da)
JP (1) JP6174995B2 (da)
CN (1) CN103025348B (da)
AU (1) AU2011247985B2 (da)
BR (1) BR112012028462A2 (da)
CA (1) CA2797126C (da)
CY (1) CY1122827T1 (da)
DK (1) DK2566505T3 (da)
ES (1) ES2764733T3 (da)
HR (1) HRP20200008T1 (da)
HU (1) HUE047288T2 (da)
LT (1) LT2566505T (da)
ME (1) ME03682B (da)
MX (1) MX336872B (da)
NZ (1) NZ603453A (da)
PL (1) PL2566505T3 (da)
PT (1) PT2566505T (da)
RS (1) RS59867B1 (da)
RU (1) RU2012152320A (da)
SI (1) SI2566505T1 (da)
SM (1) SMT202000011T1 (da)
WO (1) WO2011140429A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
JP2021501793A (ja) * 2017-11-07 2021-01-21 アルファコア ファーマ リミテッド ライアビリティ カンパニーＡｌｐｈａｃｏｒｅ Ｐｈａｒｍａ Ｌｌｃ 心疾患、心血管疾患及び関連する病状と症状を治療し保護する方法
EP4259280A4 (en) * 2020-12-11 2025-02-12 The Regents Of The University Of Michigan Compositions and methods for preventing, attenuating, and treating medical conditions with shdl nanoparticles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000110A1 (en) * 1996-07-03 1998-01-08 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
DE69836626T2 (de) * 1997-04-11 2007-04-05 Takeda Pharmaceutical Co. Ltd. Proteine mit lecithin-cholesterin acetyltransferase-ähnlicher aktivität, deren herstellung und verwendung
CN1561218A (zh) * 2001-07-27 2005-01-05 努特里奇亚有限公司 用于预防和/或治疗败血症的肠道组合物
IL158554A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Mimetic lipids as dietary supplements
WO2005097805A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
ES2559353T3 (es) * 2007-07-26 2016-02-11 Amgen, Inc Enzimas lecitina-colesterol aciltransferasa modificadas
WO2009124055A1 (en) * 2008-03-31 2009-10-08 University Of Chicago Human apoa-i mutants
US8492108B2 (en) * 2009-06-12 2013-07-23 Bruce J. Auerbach Methods of treating anemia and red blood cell dysfunction with lecithin cholesterol acyltransferase

Also Published As

Publication number Publication date
CN103025348A (zh) 2013-04-03
ME03682B (me) 2021-01-20
JP2013528594A (ja) 2013-07-11
EP2566505A1 (en) 2013-03-13
SI2566505T1 (sl) 2020-03-31
CA2797126C (en) 2020-06-02
EP2566505B1 (en) 2019-10-16
NZ603453A (en) 2014-12-24
WO2011140429A1 (en) 2011-11-10
CN103025348B (zh) 2015-09-02
RU2012152320A (ru) 2014-06-20
CY1122827T1 (el) 2021-05-05
MX2012012711A (es) 2012-11-21
ES2764733T3 (es) 2020-06-04
US20130045194A1 (en) 2013-02-21
US20150190479A1 (en) 2015-07-09
PL2566505T3 (pl) 2020-06-29
SMT202000011T1 (it) 2020-03-13
AU2011247985B2 (en) 2015-12-03
RS59867B1 (sr) 2020-03-31
BR112012028462A2 (pt) 2016-07-19
HUE047288T2 (hu) 2020-04-28
LT2566505T (lt) 2020-02-10
JP6174995B2 (ja) 2017-08-02
HRP20200008T1 (hr) 2020-03-20
AU2011247985A1 (en) 2012-11-29
PT2566505T (pt) 2020-01-15
CA2797126A1 (en) 2011-11-10
MX336872B (es) 2016-02-04

Similar Documents

Publication Publication Date Title
HUS1900001I1 (hu) Transztiretin expressziójának módosítása
IL225867B (en) Coelenterazine substrates
EP2675909A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en) Stevia-COMPOSITION
BR112013002845A2 (pt) combinação de susbtâncias ativas
EP2713762A4 (en) Stevia-COMPOSITION
EP2622818A4 (en) EXPANSION OF ATTENTION COMMANDS
LT3222272T (lt) Farmacinė karbetocino kompozicija
DK2569154T3 (da) Flerlags støbt legeme af træfiner
DK2633006T3 (da) Fremstilling af fornybart bio-destillat
DK2755481T3 (da) Anvendelse af alginatoligomerer til at forøge virkningerne af svampemidler
DK2555704T3 (da) Visning af hæmostatiske parametre
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
DK2627673T3 (da) Terapier til forbedring af lungefunktionen
FI20105639A0 (fi) Mikroselluloosan valmistus
EP2635269A4 (en) COMBINATION COMPOSITION
FR2957252B1 (fr) Composition cosmetique
EP2623092A4 (en) COSMETIC COMPOSITION
DK2453858T3 (da) Fremgangsmåde
DK3446565T3 (da) Fremgangsmåder til behandling af antipsykotika-induceret vægtøgning
EP2563347A4 (en) TRANSDERMAL PROPYNYLAMINOINDANE COMPOSITIONS
DK2571843T3 (da) Forbedret fremstilling af chalcon-derivater
HRP20182057T1 (hr) Temperaturno stabilni vodeni pripravci klokintocet-meksila
DK2655360T3 (da) Fremgangsmåde til fremstilling af n-sulfonylsubstituerede oxindoler